ClinicalTrials.gg
Not yet recruitingNCT07682129ELEVATE-LTEUpdated Jul 2, 2026

Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

A Phase 2 interventional study of ENTR-601-44 and ENTR-601-45 in Duchenne Muscular Dystrophy (DMD), sponsored by Entrada Therapeutics, Inc.. Not yet recruiting at 17 sites in 5 countries. Open to male participants aged 4 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Entrada Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
4 Years to 20 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom — 16 open to participants now, 26 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United Kingdom.

Planned enrollment
33rd of 73
80 · median 74
Started
2026
with 3 others
Phase 2
23 of 85
5 open now
Primary completion
2032-03
later than 24 of 25 live
Registered
85th of 85
by date
Lead sponsor
3 of 85
Entrada Therapeutics, Inc.

Among the 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom, this one is the 33rd largest by planned enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 in phase 2, reaches primary completion later than 24 of the 25 other live ones, and was the 85th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

16 of the 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 20 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a study of investigational medicines ENTR-601-44 and ENTR-601-45 designed to evaluate the long-term safety and tolerability of study drugs in participants with Duchenne muscular dystrophy (DMD).

The investigational medicines are currently being investigated in multiple ascending dose parent studies. After participants complete their respective parent study, there is a need to understand the effects of long-term administration of ENTR-601-44 and ENTR-601-45.

Participants enrolling in this study will begin this long-term extension (LTE) study at the dose level they received upon completion of the parent study with possible dose escalation in the LTE study based on emerging safety and efficacy data from the parent studies.

Participants will:

  • Receive study treatment in the form of multiple intravenous (IV) infusions (slow injections) into a vein over the course of several weeks
  • Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, and excersice tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a results of the study drug.

Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)

Keywords

  • Duchenne Muscular Dystrophy
  • DMD
  • Exon 44 skipping
  • Exon 45 skipping
  • exon skipping therapy
  • oligonucleotide therapy
04

Who can participate

Ages eligible
4 Years to 20 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide consent (if at age of majority) or assent (if a minor)
  • Participant completed clinical study ENTR-601-44-201 or ENTR-601-45-201
  • Males who are sexually active with a female partner of must agree to use condoms during sexual intercourse

Exclusion criteria

Exclusion Criteria:

  • Any change from the applicable parent study eligibility criteria, including safety events during the parent study, that in the opinion of the investigator in consultation with the medical monitor and/or sponsor designee precludes safe use of study drug
  • Participant has a condition or circumstance that in the view of the investigator places the subject at high risk of poor treatment compliance or for not completing the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    ENTR-601-44

    ENTR-601-44 intravenous infusion every 6 weeks

    Drug: ENTR-601-44

  • Experimental
    ENTR-601-45

    ENTR-601-45 intravenous infusion every 6 weeks

    Drug: ENTR-601-45

Interventions

  • DrugENTR-601-44

    ENTR-601-44 intravenous infusion

  • DrugENTR-601-45

    ENTR-601-45 intravenous infusion

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period)

    Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.

    Time frame: From baseline through End of Study (up to 2 years).

Secondary outcomes

  1. Plasma concentration of study drug compounds and their final metabolite

    Time frame: From baseline through End of Study (up to 2 years).

  2. Change from parent study Part A and OL Period baselines to LTE EOS in 10-Meter Walk/Run (10MWR)

    Time frame: From baseline through End of Study (up to 2 years).

  3. Change from parent study Part A and OL Period baselines to LTE EOS in timed rise from floor (TRF)

    Time frame: From baseline through End of Study (up to 2 years).

  4. Change from parent study Part A and OL Period baselines to LTE EOS in Timed 4-Stair Climb (4SC)

    Time frame: From baseline through End of Study (up to 2 years).

  5. Change from parent study Part A and OL Period baselines to LTE EOS in stride velocity 95th centile (SV95C)

    Time frame: From baseline through End of Study (up to 2 years).

  6. Change from parent study Part A and OL Period baselines to LTE EOS in North Star Ambulatory Assessment (NSAA)

    Time frame: From baseline through End of Study (up to 2 years).

  7. Change from parent study Part A and OL Period baselines to LTE EOS in Performance of the Upper Limb v2.0 (PUL 2.0)

    Time frame: From baseline through End of Study (up to 2 years).

  8. Anti-drug antibody (ADA) and anti-dystrophin antibody in serum

    Time frame: From baseline through End of Study (up to 2 years).

07

Study locations

17 sites
08

References and documents

Individual participant data

Plan to share: No — The datasets generated during and/or analyzed during the current study are not expected to be made available due to the data´s high commercial sensitivity.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Mar 2032, 67 months later.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 67 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jul 2, 2026
StartEst.
Aug 2026
Primary completionEst.
Mar 2032
CompletionEst.
Mar 2032
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07682129
Lead sponsor
Entrada Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Aug 2026 (estimated)
Primary completion
Mar 2032 (estimated)
Completion
Mar 2032 (estimated)
Last update
Jul 2, 2026

Study contacts

Entrada Therapeutics Clinical Trials
study director · Entrada Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion